


Section: [8. Immunomodulators and antineoplastics](#) > [8.2. Antineoplastics and supportive medicines](#) > [8.2.4. Hormones and antihormones](#)

EMLc

ATC codes: [H02AB09](#)

Indication	Lymphoid leukaemia, not elsewhere classified	ICD11 code: 2C03.3
INN	Hydrocortisone	
Medicine type	Chemical agent	
List type	Complementary (EML) (EMLc)	
Formulations	Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)	
EML status history	First added in 2015 (TRS 994)	
Sex	All	
Age	Also recommended for children	
Therapeutic alternatives	The recommendation is for this specific medicine	
Patent information	Patents have expired in most jurisdictions Read more about patents . 	

Tags

Cancer

Wikipedia

[Hydrocortisone](#) 

DrugBank

[Hydrocortisone](#) 

Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for hydrocortisone on the complementary list of the EML and EMLc for use in treatment protocols for acute lymphoblastic leukaemia (ALL) was recommended. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for ALL is attached.

[Expert Committee report](#) 